Background: Chronic kidney disease (CKD) is a risk factor for adverse drug events. The clinical significance of discordance between renal prescribing references is unknown. Aim: We determined the prevalence of potentially inappropriate prescribing (PIP) in CKD, measured agreement between two prescribing references, and assessed potential for harm consequent to PIP. Design: Single-centre observational study. Methods: A random sample of hospitalized patients with CKD were grouped according to baseline CKD stage (3, 4, or 5). Prescriptions requiring caution in CKD were referenced against the Renal Drug Handbook (RDH) and British National Formulary (BNF) to identify PIP (non-compliance with recommendations). Inter-reference agreement was measured using percentage agreement and Kappa coefficient. Potential for harm consequent to PIP was assessed by physicians and pharmacists using a validated scale. One-year mortality was compared between patients with or without PIP during admission. Results: Among 119 patients (median age 73 years, 50% male), 136 cases of PIP were identified in 78 (65.5%) patients. PIP prevalence, per patient, was 64.7% using the BNF and 28.6% using the RDH (fair agreement, Kappa 0.33, P < 0.001). The majority (63.2%) of PIP cases detected exclusively by the BNF carried minimal or no potential for harm. PIP was not significantly associated with one-year mortality (34.7% vs. 21.1%, P ¼ 0.14). Conclusions: PIP was common in hospitalized patients with CKD. Substantial discordance between renal prescribing references was apparent. The development of universally-adopted, evidence-based, prescribing guidelines for CKD might optimize medications safety in this vulnerable group.
Introduction
Chronic kidney disease (CKD) is associated with increased morbidity, mortality and healthcare expenditure. 1 Patients with CKD are subjected to complex pill-regimens, altered pharmacokinetic drug handling and a predilection to develop nephrotoxicity. [2] [3] [4] [5] Furthermore, inappropriate prescribing is estimated to affect between 13 and 81% of hospitalized patients with renal impairment [6] [7] [8] [9] [10] [11] and CKD is a reported risk factor for in-hospital adverse drug events. 12 Prescribing references offer inconsistent recommendations with respect to medications use in CKD. Substantial disagreement between references, and a poor evidence basis for many prescribing recommendations, have been reported. 13, 14 However, the clinical significance of inter-reference discordance has not formally been examined. We hypothesize that the prevalence of potentially inappropriate prescribing (PIP) in hospitalized patients with CKD is strongly influenced by choice of prescribing reference. We furthermore posit that inconsistencies between references might differ depending upon severity of CKD, potential for harm consequent to PIP, or drug class. Better understanding of the clinical impact of inter-reference discordance might help to prioritize and guide the development of universal, evidence-based, prescribing guidelines for patients with CKD.
We, therefore, examined medication prescribing in hospitalized patients with CKD according to two popular renal prescribing references, the British National Formulary (BNF) and the Renal Drug Handbook (RDH). We aimed to determine the prevalence of PIP using either reference; to rate the potential for harm consequent to each case of PIP; and to measure agreement between references with respect to PIP detection, according to CKD stage, potential for harm consequent to PIP and Anatomical Therapeutic Chemical (ATC) drug class. As a secondary outcome, we compared mortality 1 year following the index admission among patients with or without PIP. 17, 18 Prescription data for active drugs at each time point included name, dose, frequency and ATC class. One-year mortality from the date of PIP determination was examined using the hospital's patient information management system. For quality control, independent double data entry was undertaken on 10% of cases.
Materials and methods

Study population and data sources
Outcome assessment
Prescriptions were referenced against the contemporaneous BNF 19 and RDH. 20 By convention, Cockcroft Gault CrCl was used when referencing the RDH and MDRD eGFR when referencing the BNF, unless the reference specified otherwise. Drugs were designated as renal risk drugs (RRD) if they required dose adjustment, frequency of administration adjustment, or were contraindicated, in patients with renal impairment. PIP was defined as a RRD prescription deviating from either BNF or RDH recommendations. PIP was identified at three time points: at admission (based on the first creatinine value following hospital admission); during admission (based on the creatinine value on the day of patient randomization to the study); and at discharge (based on the creatinine value immediately preceding discharge). We appraised only RRDs where PIP could be assessed from the prescription, independent from other observations e.g. blood pressure, heart rate, blood glucose. Efforts were made to contact patients' treatment teams to facilitate remediation of identified PIP. For dialysed patients, the relevant section of the RDH monograph regarding dialysis modality was referenced. When referencing the BNF, prescribing recommendations were supplemented with relevant authorized Summary of Product Characteristics documents, as consultation with 'specialist literature' when prescribing for this patient group is explicitly advised. As appropriate, we also appraised the prescribing in the context of the day(s) the patient received dialysis treatment.
All PIP cases were retrospectively and independently reviewed by two clinical pharmacists (TG, DD) and two, from a pool of three, physicians (MOS, NA, PL) using a validated visual analogue scale (0 ¼ no harm, 10 ¼ death) to identify potential for harm consequent to PIP. 21 The mean of the four independent scores was calculated and then categorized according to potential to cause minor (0-3), moderate (3-7) or severe (>7) harm. If a patient experienced multiple cases of PIP, the highest scoring PIP was used to describe the potential for harm consequent to PIP for that patient. Agreement between prescribing references for PIP detection during admission was our primary study outcome, and was determined both at the patient level (i.e. whether a patient had at least one case of PIP) and at the drug level (i.e. whether a drug prescription represented a case of PIP). We also measured agreement between references in pre-defined sub-groups (CKD stage, potential for harm consequent to PIP, ATC drug class) as secondary study outcomes, and measured one-year mortality from the date of PIP determination, comparing patients with PIP to those without PIP.
Statistical analysis
Categorical variables were expressed as frequencies and percentages and compared using Chi-square or Fischer Exact testing, as appropriate. Data distributions for continuous variables were examined using histograms and Kolmogorov-Smirnov testing. All were non-normal and, accordingly, reported as a medians (interquartile ranges, IQRs) and compared using Mann-Whitney U or Mood's Median Test. Agreement between prescribing references was reported as percentage agreement and as an unweighted
.61-0.80 ¼ 'substantial' and.81-1.00¼ 'almost perfect').
22 A 2-sided P values < 0.05 was considered statistically significant. IBM SPSS version 22 (Armonk, New York) was used to support data analysis. This study was approved by the institution's Research Ethics Committee. Data were collected by study investigators (NA, JOR, EPD, LM, TG) and were de-identified at entry to the study database.
Results
Patient characteristics
Baseline demographic and clinical characteristics of the 119 studied patients are summarized in Table 1 ). The most common documented reasons for admission were relating to infection, cardiovascular disease, malignancy and acute kidney injury or need to commence maintenance dialysis (data not shown).
Agreement between prescribing references
In total, 1 539 medications, including 567 RRDs, were prescribed on the day of primary data collection, representing a median of 13 medications (IQR 9-16) and 5 RRDs (IQR 3-6) per patient, Table 2 . Examples of PIP, focusing on two selected patients with dialysis-requiring stage 5 CKD, are provided in the Appendix. Among the RRDs, 41 PIP cases affecting 34 (28.6%) patients were identified by the RDH vs. 132 cases affecting 77 (64.7%) patients by the BNF, Table 2 . The majority of cases (37 of 41, 90.2%) identified by the RDH were also identified by the BNF. Conversely, only 37 of 132 (28.0%) cases identified by the BNF were also identified by the RDH. Overall, agreement between references was fair: kappa 0.36 at the prescription level (P < 0.001) and 0.33 at the patient level (P < 0.001). Findings for dialysis patients only are provided in Supplementary Table 2 .
Assessment of potential for harm consequent to PIP identified four prescriptions (0.7% of RRD prescriptions) with potential for severe harm, 67 (11.8%) with potential for moderate harm, and 65 (11.5%) with potential for minor or no harm. Potential for harm at the patient level is described in Table 2 . Agreement between references was perfect for the four cases with potential for severe harm, but poor for cases with potential for moderate harm (agreement in 28 of 67 cases, kappa ¼ -0.12, P ¼ 0.031) or for minimal or no harm (agreement in 5 of 65 cases, kappa ¼ 0.003, P ¼ 0.771). Of the 95 PIP cases identified exclusively by the BNF, and not by the RDH, 60 (63.2%) had potential for minimal or no harm, 35 (36.8%) for moderate harm and none for severe harm. All 4 PIP cases identified exclusively by the RDH, and not the BNF, carried potential for moderate harm. PIP prevalence, by patient, was 50.9%, 70.4%, and 83.8% in stages 3, 4 and 5, CKD, using either reference, P ¼ 0.004. PIP prevalence did not differ significantly by CKD stage using the RDH (25.5%, 29.6%, 32.4%, respectively, P ¼ 0.76) but was more prevalent in stages 4 and 5 CKD (49.1%, 70.4% and 83.8%, respectively, P ¼ 0.005) using the BNF, Table 2 . Agreement between references, at either the patient or drug level, was poorest in patients with stage 5 CKD. PIP prevalence also differed across ATC drug classes, and differentially so depending upon the reference used, although anti-bacterials (J01) and analgesics (N02) were the most commonly implicated drug classes using either reference (Figure 1 ). Agreement between references was highest for ATC chapters L (antineoplastic and immuno-modulating, 100% agreement) and J (anti-infectives for systemic use, 92% agreement) and lowest for R (respiratory, 33% agreement) and C (cardiovascular system, 75% agreement).
Phases of care
Medication data at three phases of care (at admission, during admission, at discharge) were available for 80 (67.2%) of the cohort. Using the RDH, the proportion of patients experiencing PIP was lower at admission (13.8%) or at hospital discharge (22.5%) than during admission (26.3%). Using the BNF, the proportions at admission, during admission, and at discharge were 51.3%, 65.0% and 55.0%, respectively.
One year all-cause mortality
One year follow-up data were available for 110 (92.4%) of the cohort. One year all-cause mortality was 34.7% among patients who experienced PIP vs. 21.1% among those who did not (P ¼ 0.137).
Discussion
We identified significant discordance between prescribing references with respect to prescribing recommendations for medications requiring caution in renal impairment in a population of 119 hospitalized patients with CKD. Detection of PIP and determination of potential for harm consequent to PIP differed considerably depending upon the reference used. Agreement improved when only cases with potential to cause moderate or severe harm were considered, although disimproved with advancing severity of CKD. One-year mortality was not significantly higher in patients who experienced PIP, although the independent effect of PIP on mortality was not evaluated.
Previous studies have examined PIP in hospitalized patients with CKD, although heterogeneity with respect to patient characteristics and outcome-related definitions have resulted in discrepant findings. [6] [7] [8] [9] [10] [11] 23, 24 The PIP prevalence of between 29% and 64% (depending upon the reference used) we identified in this study is within the wide range of 13-81% previously reported, suggesting that prescribing reference source might be another factor explaining inter-study variability.
Ours is not the first study to report inconsistencies between prescribing references with respect to renal dosing recommendations. 13, 14 Novel to this study, however, was the translation of theoretical inconsistencies to a clinical setting. Our observation that most excess PIP cases identified exclusively by the BNF were deemed to have minimal or no potential for harm, and that all cases detected by the RDH had at least the potential for moderate harm, suggests that the RDH adopts a substantially higher threshold when considering the need for dose-adjustment or drug avoidance in renal impairment. Whether rigid adherence to more stringent recommendations protects patients by avoiding PIP, or potentially harms patients by depriving them of lifesaving or life-prolonging medications (e.g. anti-bacterials, statins or aspirin) should be the focus of further study. Our finding that PIP is perpetuated from time of admission to the hospital right through to hospital discharge is consistent with prior reports examining care at some of these phases, 25, 26 but was counter to a recent finding from Doody and colleagues that the prevalence of PIP decreased from admission to discharge. 11 We thus identified multiple temporal opportunities for patient safety interventions. We also confirmed, in our local setting, that anti-thrombotics, 9,27 anti-bacterials 7,9,10,27-29 and analgesics 7 were the most commonly implicated drug classes contributing to PIP. The four cases of PIP with potential to cause severe harm in our study cohort affected three patients being treated for malignancies who were prescribed non-steroidal anti-inflammatory drugs (NSAIDs) and/or low molecular weight heparins. This finding is consistent with evidence identifying NSAIDs and anticoagulants as among the top ten high-risk medications associated with fatal medication error. 30 Our study was not adequately powered to detect a mortality difference between patients who did or did not experience PIP, nor were we powered to adjust for confounders of any potential association. However, we suggest that our finding of a numerically higher mortality risk in patients who experienced PIP is hypothesisgenerating. We advocate for further research focusing specifically on associations between PIP and mortality in CKD cohorts. Our study has several limitations. First, we determined potential, rather than manifest, harm consequent to PIP, as appropriate in prospective research. 21 Second, our data were derived from a single academic centre serving a predominantly Caucasian population and operating in an absence of inpatient electronic prescribing or computerized clinical decision support. Thus the generalizability of our findings to other patient populations, healthcare systems, or processes for prescribing, remains unknown. Third, we used creatinine-based measures of renal function (MDRD eGFR and Cockcroft Gault CrCl) to define our study groups and to determine prescribing appropriateness. These measures may not be valid in hospitalized patients in whom creatinine generation or glomerular filtration are not necessarily in a steady state. 31 Nevertheless, these estimates of renal clearance are commonly used in clinical practice and thus our study findings retain validity and pragmatic utility when interpreted with this limitation in mind. 15 In summary, our study findings demonstrate that up to two thirds of hospitalized patients with CKD stages 3, 4 or 5 experience PIP, but that the prevalence of PIP and the potential for harm consequent to PIP differ considerably depending upon the prescribing reference used. Variations in PIP prevalence were also observed across CKD stages, drug classes, and phases of hospital care, identifying multiple opportunities to target high risk groups for intervention and to optimize medications safety. As advocated in a Kidney Disease: Improving Global Outcomes position paper, 3 we highlight the need for additional pharmacokinetic/pharmacodynamic studies in patients with CKD, along with the establishment of a registry collecting drug safety and efficacy outcome data in this population. These efforts could inform the development of universal, evidence-based, renal prescribing guidelines, leading to safer, standardized prescribing and enhanced patient care.
